EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clinical application of immunogenic cell death inducers in cancer immunotherapy: turning cold tumors hot

Yiman Han, Xin Tian, Jiaqi Zhai, Zhenyong Zhang

Frontiers in Cell and Developmental Biology · 07.05.2024 · 12

DOI: 10.3389/fcell.2024.1363121 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 07.05.2024. Verfasst von Yiman Han und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy has emerged as a promising cancer treatment option in recent years. In immune “hot” tumors, characterized by abundant immune cell infiltration, immunotherapy can improve patients’ prognosis by activating the function of immune cells. By contrast, immune “cold” tumors are often less sensitive to immunotherapy owing to low immunogenicity of tumor cells, an immune inhibitory tumor microenvironment, and a series of immune-escape mechanisms. Immunogenic cell death (ICD) is a promising cellular process to facilitate the transformation of immune “cold” tumors to immune “hot” tumors by eliciting innate and adaptive immune responses through the release of (or exposure to) damage-related molecular patterns. Accumulating evidence suggests that various traditional therapies can induce ICD, including chemotherapy, targeted therapy, radiotherapy, and photodynamic therapy. In this review, we summarize the biological mechanisms and hallmarks of ICD and introduce some newly discovered and technologically innovative inducers that activate the immune system at the molecular level. Furthermore, we also discuss the clinical applications of combing ICD inducers with cancer immunotherapy. This review will provide valuable insights into the future development of ICD-related combination therapeutics and potential management for “cold” tumors.

Schlagwörter

Stichwörter der Autor:innen

cancer immunotherapyclinical applicationimmunogenic cell death (ICD)immunosuppressive tumorsinducerstumor microenvironment (TME)

Autor:innen und Institutionen

  • Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.

Zitieren

APA

Han, Y., Tian, X., Zhai, J., & Zhang, Z. (2024). Clinical application of immunogenic cell death inducers in cancer immunotherapy: turning cold tumors hot. Frontiers in Cell and Developmental Biology, 12. https://doi.org/10.3389/fcell.2024.1363121

Vancouver

Han Y, Tian X, Zhai J, Zhang Z. Clinical application of immunogenic cell death inducers in cancer immunotherapy: turning cold tumors hot. Frontiers in Cell and Developmental Biology. 2024;12. doi:10.3389/fcell.2024.1363121

BibTeX
@article{Han2024,
  author = {Han, Yiman and Tian, Xin and Zhai, Jiaqi and Zhang, Zhenyong},
  title = {Clinical application of immunogenic cell death inducers in cancer immunotherapy: turning cold tumors hot},
  journal = {Frontiers in Cell and Developmental Biology},
  year = {2024},
  volume = {12},
  doi = {10.3389/fcell.2024.1363121}
}
Kostenlos starten →